Key Points
- CEO Daniel Antonio Perez sold 45,456 shares of Hinge Health on May 7 at an average price of $55.05, totaling about $2.5 million. The sale cut his ownership by 56.17% and was made under a pre-arranged Rule 10b5-1 plan.
- Hinge Health reported stronger-than-expected quarterly results, posting $0.45 EPS versus the $0.12 consensus estimate and revenue of $182.31 million, up 47.2% year over year. The company also beat the prior year’s earnings, though profitability metrics remained negative.
- Analysts remain mostly bullish on the stock, with several firms raising price targets and the consensus rating sitting at “Moderate Buy.” The average target price is $67.40, above the recent trading level around $55.89.
Hinge Health Inc. (NYSE:HNGE - Get Free Report) CEO Daniel Antonio Perez sold 45,456 shares of the business's stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $55.05, for a total value of $2,502,352.80. Following the completion of the sale, the chief executive officer owned 35,470 shares of the company's stock, valued at approximately $1,952,623.50. This trade represents a 56.17% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Daniel Antonio Perez also recently made the following trade(s):
- On Wednesday, May 6th, Daniel Antonio Perez sold 104,544 shares of Hinge Health stock. The stock was sold at an average price of $55.09, for a total value of $5,759,328.96.
- On Thursday, February 12th, Daniel Antonio Perez sold 166,665 shares of Hinge Health stock. The stock was sold at an average price of $40.26, for a total value of $6,709,932.90.
Hinge Health Stock Performance
HNGE opened at $55.89 on Friday. The business has a 50 day moving average price of $42.81 and a 200 day moving average price of $44.00. Hinge Health Inc. has a twelve month low of $30.08 and a twelve month high of $62.18. The firm has a market cap of $4.40 billion and a P/E ratio of -4.53.
Hinge Health (NYSE:HNGE - Get Free Report) last posted its earnings results on Tuesday, May 5th. The company reported $0.45 earnings per share for the quarter, topping the consensus estimate of $0.12 by $0.33. Hinge Health had a negative return on equity of 279.39% and a negative net margin of 78.95%.The firm had revenue of $182.31 million during the quarter. During the same quarter last year, the firm posted $1.30 earnings per share. The firm's revenue for the quarter was up 47.2% compared to the same quarter last year. As a group, analysts anticipate that Hinge Health Inc. will post 0.78 earnings per share for the current fiscal year.
Analyst Ratings Changes
A number of research analysts have recently commented on the company. Citigroup reiterated an "outperform" rating on shares of Hinge Health in a report on Wednesday. Piper Sandler reiterated an "overweight" rating and set a $95.00 price target on shares of Hinge Health in a report on Wednesday. Royal Bank Of Canada upped their price target on Hinge Health from $55.00 to $65.00 and gave the stock an "outperform" rating in a report on Wednesday. Canaccord Genuity Group upped their price target on Hinge Health from $53.00 to $63.00 and gave the stock a "buy" rating in a report on Wednesday. Finally, Freedom Capital upgraded Hinge Health to a "strong-buy" rating in a report on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $67.40.
Read Our Latest Report on HNGE
Institutional Trading of Hinge Health
Institutional investors and hedge funds have recently modified their holdings of the company. Vanguard Group Inc. increased its position in shares of Hinge Health by 22.6% during the third quarter. Vanguard Group Inc. now owns 1,237,839 shares of the company's stock valued at $60,753,000 after purchasing an additional 228,234 shares during the period. Tudor Investment Corp ET AL increased its position in shares of Hinge Health by 25.9% during the third quarter. Tudor Investment Corp ET AL now owns 376,266 shares of the company's stock valued at $18,467,000 after purchasing an additional 77,464 shares during the period. First Eagle Investment Management LLC bought a new stake in shares of Hinge Health during the third quarter valued at approximately $4,074,000. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Hinge Health by 755.1% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 27,354 shares of the company's stock valued at $1,271,000 after purchasing an additional 24,155 shares during the period. Finally, Braidwell LP bought a new stake in shares of Hinge Health during the third quarter valued at approximately $44,686,000.
About Hinge Health
(
Get Free Report)
Hinge Health (NYSE: HNGE) is a digital musculoskeletal (MSK) clinic that provides end-to-end solutions for the prevention and management of musculoskeletal conditions. The company's platform combines wearable motion sensors, personalized exercise therapy guided by licensed physical therapists, and behavioral health coaching to deliver tailored treatment plans. By integrating technology with evidence-based clinical protocols, Hinge Health aims to reduce pain, improve mobility and decrease reliance on more invasive interventions such as surgery or opioid prescriptions.
Founded in 2015 and headquartered in San Francisco, Hinge Health partners with employers, health plans and other payers to offer its self-directed, app-based programs.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
